DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/zmvd7k/diabetic_macular) has announced the addition of the “Diabetic Macular Edema – Pipeline Review, H2 2015” report to their offering. This report provides comp…
The Dompé biopharmaceutical company has announced that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth…
NEW YORK — At OSN New York 2015, Elizabeth Yeu, MD, gives pearls on when to use different types of capsular tension rings and segments during cataract surgery.
(MedPage Today) — But with a veto waiting in the wings, is this a pyrrhic victory?
(MedPage Today) — But with a veto waiting in the wings, is this a pyrrhic victory?
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, announced today that on December 1, 2015, the Board of Directors approved the grant of 190,000 inducement restricted stock units (“RSUs”) to Will McGuire, the Company’s Chief Executive Officer. The award will vest over four years, with 25 percent (25%) of the